Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide for NTM, Burkholderia, Aspergillus, and COVID-19
NCT03331445Phase 2Terminated
- Sponsor
- Chris Miller
- Start
- Oct 2017
- Primary completion
- Jun 2021
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nitric oxide in Nontuberculous Mycobacterial Lung Disease (NTM-LD), Burkholderia infection, pulmonary aspergillosis and 1 more, sponsored by Chris Miller. Primary endpoints: Unanticipated Adverse Events at 26 Days and Change in FEV1% Predicted at 26 Days. Started Oct 2017; status: terminated.
02
Drugs
nitric oxide
03
Conditions
Nontuberculous Mycobacterial Lung Disease (NTM-LD)Burkholderia infectionpulmonary aspergillosiscoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT03331445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03331445.